Whereas several studies have demonstrated that expression of HER2 and HER3 is correlated with clinicopathological factors and poor prognosis [31,32], results from the CALGB 80,203 trial showed that high tumor mRNA levels of HER2 is a prognostic marker associated with longer progression free survival across all mCRC patients in this study [33]. The gene discussed is ERBB2; the disease is neoplasm.